(BUSINESS WIRE)– The Board of Directors of the parent company of Kinetic Concepts, Inc. and LifeCell Corporation today announced that Ronald A. Matricaria has joined the Board of Directors and will serve as its Chairman. Matricaria will oversee the implementation of a new management structure under which Joseph F. Woody has been appointed President and Chief Executive officer of KCI and Lisa N. Colleran has been appointed President and Chief Executive Officer of LifeCell. Martin J. Landon, who served as interim Chief Executive Officer during the recent management transition, will continue in his capacity as Executive Vice President and Chief Financial Officer of KCI. In addition, the Board of Directors announced that KCI will pursue strategic alternatives for KCI’s Therapeutic Support Systems business.

The structure and plans announced today are designed to strengthen the companies’ performance and deliver stronger returns while ensuring that KCI and LifeCell remain recognized leaders in the fields of wound care and regenerative medicine. KCI and LifeCell are privately-held sister corporations owned by a consortium consisting of Apax Partners and controlled affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board. Going forward, KCI and LifeCell financial reporting will remain consolidated, while the companies will be managed independently under the new structure. KCI will continue to provide inter-company services and compliance oversight to LifeCell.

Ron Matricaria’s highly successful career in the healthcare industry has spanned nearly four decades. From 1993 to 2002, Matricaria was President and Chief Executive Officer and then Chairman of St. Jude Medical, Inc. He led the company’s diversification strategy to become a broad-based cardiovascular device company, which today is a world market leader in cardiac surgery, cardiac rhythm management, and vascular closure products and services. Prior to joining St. Jude Medical, Matricaria spent 24 years at Eli Lilly and Company, where he last served as President of North American Operations and Executive Vice President of the pharmaceutical division. Matricaria currently serves as Lead Director of the Board of Directors of LIFE Technology Corporation, Chairman of the Board of Volcano Therapeutics, Inc. and as a director on the Board of Directors of Phoenix Children’s Hospital. He also serves as an Adjunct Lecturer at Northwestern University’s Farley Center for Entrepreneurship and Innovation.

“Ron Matricaria has a proven track record of success in the medical device industry and a wealth of experience in the corporate governance of health care companies,” said Buddy Gumina, Partner and co-head of the Apax Healthcare Team. “We believe that bringing Ron on as Chairman, together with the appointment of Joe Woody and Lisa Colleran to the CEO roles at KCI and LifeCell, creates the ideal environment for outstanding success.”

Woody has more than 20 years experience in the healthcare sector. Prior to joining KCI as President of its Active Healing Solutions business in November 2011, Woody served as Global President, Vascular Therapies for Covidien. At Covidien, he was responsible for the $2.6 billion acquisition and integration of ev3. Previously, Woody served as Global President, Smith & Nephew Advanced Wound Management and held other leadership positions at Alliance Imaging, Inc., Acuson and GE Medical Systems.

Colleran has been President of LifeCell since 2008, during which time LifeCell has experienced significant growth and doubled its revenue. Colleran joined LifeCell in 2002 and has held several leadership positions including Senior Vice President, Commercial Operations and Vice President, Marketing and Business Development. Previously, Colleran spent 20 years at Baxter Healthcare Corporation in various roles in sales, marketing, business development and general management including Vice President of Marketing for Baxter’s U.S. Renal business and Vice President/General Manager of the company’s Renal Pharmaceuticals business.

Coinciding with the changes in the management structure of KCI and LifeCell, the Board of Directors has approved the engagement of Credit Suisse as lead advisor, together with UBS Investment Bank, to pursue strategic alternatives for KCI’s Therapeutic Support Systems (TSS) business. KCI’s TSS business, a global leader in the support surfaces market, rents and sells specialized therapeutic support systems including hospital beds, mattress replacement systems, overlays and patient mobility devices. There can be no assurance that any transaction regarding TSS will be completed. KCI does not intend to disclose developments with respect to progress of its strategic alternatives review process until such time as the Board of Directors approves or completes a transaction or otherwise determines that further disclosure is appropriate.

“Our TSS business has enjoyed many successes over more than 35 years, and we believe that the value TSS brings to caregivers and patients can be enhanced through a transformative strategic transaction,” said Stephen D. Seidel, President, KCI Therapeutic Support Systems.

About KCI

Kinetic Concepts, Inc. is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI’s success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing and the lives of patients around the world. For more information about KCI and how its products are changing the practice of medicine, please visit www.KCI1.com.

About LifeCell

LifeCell Corporation, based in Branchburg, NJ, is a leader in regenerative medicine, develops and markets innovative tissue repair products for the reconstructive, orthopedic and urogynecologic biosurgery markets. LifeCell™ products include Strattice™ Reconstructive Tissue Matrix and AlloDerm® Regenerative Tissue Matrix for plastic, reconstructive, and general surgical applications; Cymetra® Regenerative Tissue Matrix, a particulate form of AlloDerm® Tissue Matrix suitable for injection; Repliform® Regenerative Tissue Matrix for urogynecologic surgical procedures; GraftJacket® and Conexa™ for orthopedic surgical procedures; and the SPY® Elite System for the visualization and evaluation of tissue perfusion. Additional information about LifeCell and its products is available at www.LifeCell.com.

Forward-Looking Statements

This press release may contain “forward-looking statements.” These forward-looking statements are only predictions, not historical facts, and involve significant risks and uncertainties, as well as assumptions and are not guarantees of future performance. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Actual results, levels of activity, performance, achievements and events could differ materially from those currently stated, anticipated or implied due to a number of risks and uncertainties. Important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements are specified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, including under headings such as “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other filings and furnishings made by the Company with the SEC from time to time. Except to the extent required by applicable federal securities laws, the Company undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50148100&lang=en

Contacts

KCI Corporate Communications

Kevin Belgrade, 210-216-1236

Email: kevin.belgrade@kci1.com

KCI Investor Relations

Todd Wyatt, 210-255-6157

Email: todd.wyatt@kci1.com

DUBAI, United Arab Emirates – Saturday, January 28th 2012 [ME NewsWire]

Roche Diagnostics, diagnostic division of global healthcare company Roche announced that it will set up its Middle East headquarters in Jafza and commence operations next month. The announcement was made on the sidelines of healthcare exhibition and medical congress, Arab Health in Dubai today (xxx)

Although the global market leader in in-vitro diagnostics has been present in the Middle East region for more than 30 years, the Regional Headquarters in Jafza will be Roche Diagnostics’ first facility in the Middle East.

Through a strong distributor network, Roche Diagnostics has a presence in 18 markets in the Middle East with a 20-25% market share in all of these markets. Recognising the potential of the Middle East region, Roche Diagnostics seeks to increase the quality of supply and strengthen relations with distributors and end customers by providing added support and information. In the UAE, Roche Diagnostics enjoys a continuous relationship with its long-term distributor Pharmatrade through 30 years.

Ibrahim Aljanahi, Deputy CEO, Jafza and Chief Commercial Officer said: “We are pleased to host a respected Fortune 500 Company such as Roche at Jafza. Roche is a leader in research-focused healthcare with an impressive regional presence and we believe Jafza’s unmatched connectivity, logistics and commercial advantages will support its growth in the region. The new facility will be well positioned to serve the Roche’s growing customer base andhelp it further expand its regional footprint and market share. The new move reflects the company’s trust and confidence in Jafza and we extend our full support to Roche.”

“The Middle Eastern region is a very important part of our business. We see a tremendous potential for growth in the Middle East. Therefore, we decided to open our regional headquarters in Dubai as a hub to serve our Middle Eastern countries. I am very happy about this step. The unique combination of world-class port and airport facilities was one of the most significant reasons behind the decision to locate the Roche Diagnostics’ Middle East HQ in Jafza. Jafza is one of the leading drivers in the UAE economy and Roche Diagnostics will benefit from the advantages that come with being part of a growing business community.” says Dr. Michael Heuer, President EMEA-LATAM, Roche Diagnostics.

Roche Diagnostics, Middle East will serve distribution partners and customers across the region by setting up functions for scientific and technical support, management, administration, logistics and quality control. The office will be located in Jafza 15 and expects to see 50 employees working in the Middle East Regional Headquarters by 2013.

-Ends-

About Jafza

Jafza is Economic Zones World’s flagship operation. One of the world’s largest and the fastest growing free zones, Jafza is gateway to the Middle East, Africa and South Asian markets. Supported with excellent multi-modal logistics facilities, it offers customers excellent connectivity to reach the rapidly growing markets of over 2 billion people. Established in 1985, Jafza today is spread over an area of 57 sq. km and is home to over 6700 companies, including over 120 of the Fortune Global 500 enterprises, from across the world. It is a leading driver of the burgeoning UAE economy. With its impeccable track record, Jafza stands for innovation, customer centricity, transparent operations and entrepreneurial dynamism. For more information, visit www.jafza.ae.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Contacts

Adeti Changulani,

Hasaad Communications

Mob: +971 50 429 5576

adeti.changulani@hasaad.ae

Roche Diagnostics contact

Jane Prospero

Head of Communications EMEA-LATAM

jane.prospero@roche.com

Janne Nielsen

Communications Officer, Middle East

Janne.nielsen@roche.com

INGELHEIM, Germany – Thursday, January 26th 2012 [ME NewsWire]

(BUSINESS WIRE)– FOR NON-US MEDIA ONLY

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib* in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

Afatinib* is an irreversible ErbB Family Blocker which inhibits signal transduction of all kinase receptors from the ErbB Family, and is known to play a critical role in the growth and spread of the most pervasive cancers and cancers associated with high mortality (lung, breast, and head & neck cancers). Over-expression of the Epidermal Growth Factor Receptor (EGFR, also referred to as ErbB1)1 is found in at least 90% of head and neck cancers and strongly correlates with poor prognosis and overall survival.2

Positive results from a recently presented phase II study show that afatinib* is the first targeted therapy with at least comparable anti-tumour activity to cetuximab in patients with metastatic head and neck cancer whose cancer has returned (recurrent disease) after treatment with platinum-based chemotherapy.3

Each year, approximately 560,000 cases of head and neck cancer are diagnosed worldwide, and 300,000 patients die annually.4

For patients with recurrent/metastatic disease, treatment options include systemic chemotherapy. Despite the introduction of chemotherapy in this setting approximately 30 years ago, patients with recurrent/metastatic head and neck cancer still have a poor prognosis, with a median survival of only 6-10 months.5 In locally advanced head and neck cancer, chemoradiotherapy is an important option. However, due to high recurrence rates, patients with locally advanced disease tend to also have a poor prognosis.

“Currently, approximately 50% of patients with locally advanced head and neck cancer will have a recurrence and there is an urgent need for more treatment options” said Dr Ezra Cohen, Associate Professor of Medicine at the University of Chicago Medical Center “We hope potential new treatments such as afatinib will increase the effective options for patients with head and neck cancer.”

LUX-Head & Neck 1 will evaluate, if afatinib* can prolong progression-free survival (primary endpoint) and improve overall survival in patients with recurrent/metastatic head and neck cancer who progress after platinum-based treatment.

LUX-Head & Neck 2 will evaluate, if afatinib* can prevent the recurrence of the disease and improve overall survival in patients with locally advanced disease after chemoradiotherapy.

The initiation of these phase III clinical trials represents yet another important milestone for Boehringer Ingelheim to broaden and further develop its oncology pipeline across a range of different cancers.

This expands the phase III clinical trial programme for Boehringer Ingelheim Oncology which currently includes trials with afatinib* in NSCLC and breast cancer and nintedanib* (BIBF 1120) in NSCLC and ovarian cancer.

If investigators are interested in becoming involved in the study and have potentially eligible patients, they should contact Boehringer Ingelheim at:

clintriage.rdg@boehringer-ingelheim.com

Notes to editors

About Trial Nr. 1200.43 (LUX- Head & Neck 1) and Trial Nr 1200.131 (LUX -Head & Neck 2)

LUX- Head & Neck 1 (1200.43)

http://clinicaltrials.gov/ct2/show/study/NCT01345682

A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib* versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy

LUX-Head & Neck 2 (1200.131)

http://clinicaltrials.gov/ct2/show/NCT01345669

A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib* as adjuvant therapy after chemoradiotherapy in primary unresected HPV (Human Papilloma Virus) negative patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma

About Head and Neck Cancer

Head and neck cancer is the term used to describe malignant tumours originating in the upper aerodigestive tract (UADT), including the oral cavity, larynx, pharynx and nasopharynx. The vast majority (90%) of head and neck cancers are squamous cell carcinomas (HNSCC) arising from the epithelial membranes (mucus linings) of these regions,6 and as such they have many common features relating to their aetiology and classification. Additionally, the Epidermal Growth Factor Receptor (EGFR/ErbB1), which is critical for tumour growth,7 is over-expressed in at least 90% of head and neck cancers.2

Radiotherapy in combination with platinum-based chemotherapy (most often cisplatin) – administered either as a definitive treatment or after surgery – plays a role in the management of locally advanced and/or inoperable head and neck cancers; this is known as ‘chemoradiotherapy’. Chemoradiotherapy, however, is associated with significant side effects and toxicities. In addition, locally advanced head and neck cancer is associated with a poor prognosis due to high recurrence rates.8

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centres, Boehringer Ingelheim’s commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumours and haematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. Nintedanib* (BIBF 1120) is currently in phase III clinical development in NSCLC and Ovarian cancer. Afatinib* is currently in phase III clinical development in NSCLC and breast cancer. In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing an inhibitor of polo-like kinase 1 (Plk1), volasertib*, a protein that is involved in the processes of cell division.

Boehringer Ingelheim’s oncology pipeline is evolving and demonstrates the company’s continued commitment to the disease area.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion Euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit: www.boehringer-ingelheim.comor www.thewhiteroom.info

*Afatinib, nintedanib (BIBF 1120) and volasertib are investigational compounds. Their safety and efficacy have not yet been fully established.

References

1BI data on file

2Ford, A.C. and Grandis, J.R., 2003. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck, 25, 67-73

3Seiwert TY, et al. THNO 2011; Rome, abstract PP3.4

4Boyle P. et al. World Cancer Report 2008. International Agency for Research on Cancer.

5Coleman M.P et al. 2003 EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of Oncology, 14,S5, v128-v149.

6Viviana P. Lutzky. D. J. et al., 2008. Biomarkers for Cancers of the Head and Neck. Clinical Medicine: Ear, Nose and Throat, 1,5-15.

7Normanno N. et al., 2005. The ErbB receptors and their ligands in cancer: An overview. Current Drug Targets, May, 6(3), pp.243-247.

8Bernier, J. and Cooper, J.S. 2005. Chemoradiation after Surgery for High-Risk Head and Neck Cancer Patients: How Strong Is the Evidence? The Oncologist, 10(3), pp.215-224.

Contacts

Boehringer Ingelheim GmbH

Corporate / Global Media Contact

Julia Meyer-Kleinmann

Tel.: +49 (6132) 77-8271

PRESS@boehringer-ingelheim.com

More information

www.boehringer-ingelheim.com

At the 2012 World Future Energy Summit, a group of young Emirati women showed how they are leading the way on energy and climate change in the UAE.

Alice Marsden, an attorney at Latham & Watkins, moderated a panel discussion on clean energy and climate change. The four women panelists, who come from diverse education and career backgrounds, shared their experiences and perspectives with conference attendees at the Young Future Energy Leaders Theater.

The panel was organized by the Directorate of Energy and Climate (DECC) in the Ministry of Foreign Affairs (MoFA), in collaboration with Latham & Watkins’ Women Enriching Business (WEB) initiative and the Masdar Institute’s Young Future Energy Leaders (YFEL) Program.

“WFES truly brought together leaders from around the world to discuss some very serious issues,” said Mariam Al Mutawa from DECC, the organizer of the forum.

“This panel was an obvious opportunity to highlight the work being done by women on future energy, clean energy and climate change issues in the UAE. We were able to create a dialogue between women working in these fields, and students, on how they can lead the way on these important issues, “ said Al Mutawa.

Maryam Al Balooshi from UAE’s General Civil Aviation Authority (GCAA), who is breaking gender barriers in her work, discussed how she has transitioned from working as a chemical engineer into a more political role in the aviation sector.

Mariam Al Mutawa from DECC discussed her experiences as a recent graduate of Zayed University and shared thoughts on how UAE universities could increase the number of women in clean energy careers.

Reem Al Thawadi from Emirates Wildlife Society (EWS-WWF) discussed the importance of effective communications in advancing awareness and action on issues related to the future of energy and climate change. She also described how her diverse academic and professional background helped her career.

Rouda Al Otaiba, also from DECC, rounded out the panel by sharing her experiences as a diplomat working in the task force to help bring the International Renewable Energy Agency (IRENA) to the UAE. She also represents the UAE’s interests in international multilateral negotiations related to climate and energy.

The event was held as part of the UAE’s 2012 engagement in the Clean Energy Education and Empowerment Women’s Initiative, or C3E, under the Clean Energy Ministerial—a collaboration among the 23 countries representing more than 80 percent of the world’s global greenhouse gas emissions as well as investments in clean energy.

ENDS

For further information, please go to:

www.mofa.gov.ae

About the Directorate of Energy and Climate Change (DECC): The Ministry of Foreign Affairs established a Directorate of Energy and Climate Change (DECC) in March 2010. It has three main areas of responsibility, to liaise with IRENA, to represent the UAE in international negotiations, and to support a national climate change strategy.

About Latham & Watkins’ Women Enriching Business (WEB) Initiative: Latham & Watkins’ Women Enriching Business (WEB) initiative was initially created launched in early 2006 to address the business challenges and opportunities unique to women. The dynamic initiative is designed to support women in business by creating broader networks and productive business relationships and by attracting and investing in the long-term success of women. To date, a diverse range of programs and activities have been external programs organized and sponsored by the WEB have included including substantive events, partnerships with women’s initiatives, business development training and coaching, and social events. dedicated to investing in the long-term success of women.

About Young Future Energy Leaders (YFEL): Led by Masdar Institute, YFEL focuses on raising the awareness of students and young professionals in the fields of renewable energy and sustainability.

Contacts

Shaima Al Aydarous

sh.alaydarous@mofa.gov.ae

+971 2 493 1502

 Capsule’s innovative software and hardware products automate the charting process and improve clinical workflow by seamlessly connecting medical devices to information systems across the entire healthcare enterprise. Automation of this process recovers nursing hours, improves direct patient care time, reduces charting errors, improves decision making, and increases the adoption of the EMR.

 As the leading provider of device integration, Capsule offers one of the only solutions that is truly vendor neutral; providing hospitals with the flexibility and scalability they need to connect virtually any medical device to any information system.  This is made possible through the many, long standing partnerships with virtually every medical device manufacturer and HIS vendor.  Capsule is now expanding this business strategy to develop additional strategic partnerships throughout EMEA and therefore offer the same proven, vendor neutral solution to hospitals around the world. 

 Capsule’s solution is currently installed in over 760 hospitals around the world; including over 200 in EMEA who are using Capsule’s Datacaptor™/Terminal Server solution. By developing partnerships with new HIS vendors in the region, Capsule will be able to deliver their full solution to hospitals around the globe.  “Our distributors and vendors in EMEA and the Asia Pacific region are at the center of our growth strategy,” said Olivier Zmirou, VP of Sales for EMEA for Capsule.  “We have already secured strategic relationships with numerous vendors, and we continue to work with other partners to expand our distribution and supply chain in the region.”

In the past year, Capsule has extended its growth efforts internationally with a focus in UAE, Saudi Arabia, Qatar, France, Germany, Austria, Switzerland, Denmark, the Netherlands, the United Kingdom, and Ireland.  As a result of this focus, Capsule has nearly doubled the Company’s international footprint and expanded connectivity to over 30 countries.

 About Capsule’s Solution

Capsule’s Enterprise Medical Device Connectivity Solution™ includes both electronic medical software and hardware. Connectivity options are available for all areas of the hospital—from higher acuity areas (critical care, operating room) to lower acuity areas (med-surg and general wards) to mid-acuity areas (emergency). The key components, Capsule’s DataCaptor™ Connectivity Software and the Capsule Neuron™ Platform, deliver a patient-centered solution that integrates with existing technologies and infrastructures while enhancing caregiver work processes.

 About Capsule
Capsule, A French company,  is the leading global provider of medical device connectivity solutions. The company’s innovative software and hardware products automate and improve clinical workflow by seamlessly connecting medical devices to information systems across the entire healthcare enterprise. Hospitals and healthcare systems using electronic medical records and other information systems can quickly and easily implement Capsule’s vendor neutral, scalable solution to reduce costs, increase productivity and improve patient care. A major advantage of Capsule’s solution is that it seamlessly integrates with existing technologies and clinical workflows. Founded in 1997, the company has established strong partnerships with leading medical device manufacturers and information system providers and has installed enterprise-wide solutions in over 760 hospitals in 30 countries.

visit www.capsuletech.com

 EuroBioConcept designed Chemosafe™ to ensure total protection for operators and products, to cut operating costs and to provide secure waste management.

EuroBioConcept offers turn-key solutions that meet its customers’ specific needs as well as regulatory requirements (most recently for the prestigious Curie Institute). All of its devices are developed and assembled inside its own workshops.

Chemosafe™ serving the automated production of cytotoxic drugs

The Curie Institute wanted to validate and integrate an automated system within its pharmacy department in order to improve safety in antineoplastic agent reconstitution. The Institute was pleased with an automated device installed inside an isolator, a solution suggested by EuroBioConcept in association with automaton manufacturers Medical Dispensing System. Both companies then manufactured and delivered a functional unit that was to be validated within a year.

 Chemosafe™ units comprise a large-capacity Innosté transfer isolator completed with its fully automated, H202 decontamination system operating in very short cycles, a storage zone, as well as pre-post processing and processing zones. The entire unit is kept at ISO 5 class standards and may operate under negative pressure or positive pressure. The whole system features automatic control with traceability via PC. The end products come out through a secure transfer door. The unit is equipped with sterile thermo-solderable sheathing.

 EuroBioConcept pursues its presence in the Middle East. It will be presenting its various solutions in Zabeel Hall at ARAB HEALTH, in booth ZS 58.

www.eurobioconcept.fr

The Directorate of Energy & Climate Change (DECC) of the UAE Ministry of Foreign Affairs participated at this week’s World Future Energy Summit (WFES), reinforcing its intergovernmental role as a bridge between national and global clean energy initiatives.

The Pavilion featured the expanding role of the Directorate tasked with managing the relationship with the Abu Dhabi-based International Renewable Energy Agency (IRENA). It also leads the UAE’s international engagements in climate change and clean energy, while working with domestic stakeholders to develop national clean energy and climate policies.

His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, visited the Pavilion, as did a number of high officials, including His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs; His Highness Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Education and Scientific Research.

Foreign visitors included HE Ban Ki-Moon, Secretary-General of the United Nations; HE Nassir Abdulaziz Al-Nasser, President of the United Nations General Assembly, and HE Ólafur Ragnar Grimsson, President of Iceland. They were briefed by members of the DECC team on its mandate, recent high profile work in climate negotiations, and support of IRENA’s expanding legal and infrastructural needs.

Dr. Sultan Ahmad Al Jaber, UAE Assistant Minister of Foreign Affairs, Special Envoy for Energy and Climate Change and CEO of MASDAR, said: “The Directorate’s presence at WFES reinforces the importance the Ministry of Foreign Affairs is placing on energy and climate change through the leadership of His Highness Sheikh Abdulla bin Zayed Al Nahyan.”

He added: “WFES has offered DECC an excellent opportunity to share their achievements and ambitions with domestic and international representatives of government, industry, NGOs and academia.”

The DECC team organized and participated in a number of events including the “Women Leading the Way in Clean Energy and Climate Change” workshop, presentations at the Masdar Theater, the Department of Municipal Affairs stand and others, as well as at the closing plenary session.

Summing up DECC’s participation at WFES, Thani Ahmad Al Zeyoudi, Director of DECC, commented: “Our presence at this world class event has provided us with an opportunity to showcase and advance all aspects of our work – including the enhancement of existing international and national partnerships, while forging new ones.”

He added: “The success of this outreach exercise emphasizes the extensive cooperation we receive from key departments at the Ministry of Foreign Affairs, with particular support from our protocol, legal, political and media colleagues, and other national stakeholders in the UAE suach as Masdar”

The Directorate of Energy & Climate Change was established by the UAE Ministry of Foreign Affairs in March 2010, following a detailed review of the experience of other nations in creating similar government units.

ENDS

For further information, please go to: www.mofa.gov.ae

Contacts

Shaima Alaydarous

sh.alaydarous@mofa.gov.ae

+9712 4931502

· Summit strategic platform to instigate dialogue and find solutions

· Hosted by Masdar and Reed Exhibitions, in collaboration with the International Water Association

· First Summit to be held alongside World Future Energy Summit 2013

Highness General Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi, Deputy Supreme Commander of the UAE Armed Forces, has launched the International Water Summit to be held alongside the World Future Energy Summit in January 2013.

The UAE Minister of Environment and Water, His Excellency Dr. Rashid Ahmad Bin Fahad, Dr Sultan Ahmed Al Jaber, CEO of Masdar, and Dr. Glen Daigger, President of the International Water Association (IWA) held a press conference at the World Future Energy Summit, on January 18, to make the announcement.

Also attending the press conference was Abdullah Said Al Nuaimi, Director General of the Abu Dhabi Water and Electricity Authority (ADWEA), and HE Razan Al Mubarak, Secretary General of the Environment Agency – Abu Dhabi.

His Excellency the Minister of Environment said: “As a result of the increased pressure on this valuable resource due to various factors including over population, agricultural and economic growth and the unsustainable consumption patterns, various countries around the world are currently facing real problems with water resources. Moreover, climate change has increased the pressure on this resource as well. Therefore, this launch – as a result of our visionary leadership’s drive towards achieving water security – helmed by His Highness Sheikh Khalifa bin Zayed Al Nahyan, President of the United Arab Emirates – will shed a real light on the subject.

Dr Sultan Ahmed al Jaber said: The launch of the International Water Summit by His Highness reflects the important role the UAE is playing in supporting the international efforts in answering the pressing challenges facing the world today – is a testament to the UAE’s role in shedding light on today’s relevant subjects and a clear testimony to thought leadership.”

Dr. Al Jaber added: “His Highness recently said water is more important than oil in the United Arab Emirates. This is a bold and clear signal – that an economy based on oil – is placing water at the topmost of its agenda. His Highness also made a clear call to action: that we need to enhance and increase the studies and research necessary, create strategic action plans, and find solutions to preserving this invaluable resource for future generations.

Dr Al Jaber added that His Highness had launch of the International Water Summit based on a well calculated long term strategy. He emphasized on the interconnection between energy and water – highlighting that more than 70% of overall water production and processing cost results from the energy required to desalinate, transport, store, forward and distribute water – as opposed to the energy required to desalinate water in countries that are depleted of fresh water, such as the Arab region.

Dr Sultan noted that In 2006, the leadership of Abu Dhabi mandated the establishment of Masdar– incepted to maintain the UAE’s energy leadership, and safeguard and ensure the longevity of its natural resources; elaborating that Masdar is a key component of diversify the energy mix of Abu Dhabi.

“Masdar was established to accelerate, diversify and deploy renewable energy and clean technologies towards achieving sustainability,” he said.

“And in 2008, His Highness Sheikh Mohamed bin Zayed Al Nahyan launched the World Future Energy Summit –hosted by Masdar, annually in Abu Dhabi.”

“Over the past 5 years,” he added, “the World Future Energy Summit has been providing the world with a platform that brings together world leaders, thought leaders and experts from around the globe – enhancing and catalyzing the efforts to meet world challenges, including energy security.”

“With the clear link between energy and water – alongside the success of the World Future Energy Summit and the continued progress of Masdar – the UAE leadership saw fit to create a platform for engagement dedicated solely to water and addressing its scarcity,” he added.

In his remarks, Dr Glen Daigger, President of the IWA said: “I would like to congratulate His Highness Sheikh Mohamed bin Zayed for taking such a leading step in one of the world’s most pressing issues – coping with aridity. Through Masdar, WFES and other initiatives in Abu Dhabi we have grown accustomed to seeing this young nation take leading steps to address world challenges.”

IWA is the global network of water professionals, working every day to provide water and sanitation services which create healthy living conditions, fuel the economy, protect the environment, and enhance the living conditions for the citizens of planet earth.

Highlighting the importance of the IWA’s involvement with the International Water Summit, he added: “This forum provides the opportunity for leading water professionals to share their knowledge and experience with each other, thereby advancing our ability to serve the public and the planet as rapidly as possible.”

The first International Water Summit will take place alongside the 6th World Future Energy Summit in January 2013.

Phote Caption:

Image 1.Highness General Sheikh Mohamed bin Zayed Al Nahyan,Crown Prince of Abu Dhabi,Deputy Supreme Commander of the UAE Armed Forces,UAE Minister of Environment and Water,His Excellency Dr. Rashid Ahmad Bin Fahad,Dr Sultan Ahmed Al Jaber,CEO of Masdar,and Dr.Glen Daigger,President of International Water Association(IWA)

Contacts

APCO Worldwide

Robert Gara Jr. G.H.

206.239.0111

rgara@apcoworldwide.com

BEIJING & SINGAPORE – Wednesday, January 18th 2012 [ME NewsWire]

(BUSINESS WIRE)– Quintilestoday announced the opening of a business process outsourcing (BPO) and project management center of excellence in Dalian, a major city in northeast China with a multilingual workforce and location ideally suited to serve the Japanese, Chineseand South Koreanbiopharmaceutical markets.

The Dalian office will provide data management, biostatistics, medical writing, pharmacovigilance, post-marketing safety surveillanceand back-office support for administrative functions for global and local biopharma companies. The office also will support clinical operations for study sites in northeast China.

Dalian’s strategic location and talent pool will allow Quintiles to provide clinical services in English, Japanese, Korean and Mandarin (Dalian’s local workforce is not only multilingual but also has a cultural understanding of its neighboring countries), a valuable offering for both North Asian and global customers seeking to expand in the region or who want to ensure business continuity through resource diversification.

“Following the success of Quintiles’ Bangalore BPO center, which has over 1,000 people supporting global studies, the Dalian Center of Excellence will provide a North Asia support structure for our growing business in Japan, Korea and China,” said Anand Tharmaratnam, Senior Vice President and Head of Asia Markets, Quintiles. “Furthermore, the Dalian team will be well-suited for clients seeking to diversify their outsourcing locations for business continuity assurance.”

Quintiles anticipates growing the center to 500 staff in the next several years once all services are fully established. It will be the company’s fourth hub office in Greater China (in addition to Beijing, Shanghai and Hong Kong).

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consultingand capitalsolutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

Contacts

Quintiles

Stacey Hara, Media Relations Asia Pacific, +65 6602 1583

stacey.hara@quintiles.com

Jay Johnson, Media Relations U.S., +1 919 998 2066

jay.johnson@quintiles.com

Greg Connors, Investor Relations, +1 919 998 2000

invest@quintiles.com

Abu Dhabi, United Arab Emirates – Wednesday, January 18th 2012 [ME NewsWire]

His Highness General Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, today presented the prestigious 2012 Zayed Future Energy Prize to 3 winners and 2 runners up at the awards ceremony held in Emirates Palace.

His Highness said: “The Zayed Future Energy Prize has become a beacon of light, stimulating thinkers and creators while encouraging the world to accelerate innovation in renewable energy and sustainability. This Prize is a clear manifestation of the vision of the late founding father of the United Arab Emirates, Sheikh Zayed bin Sultan Al Nahyan – who placed a priority on investing in human capital and the preservation of our natural resources for generations to come.”

His Highness added: “Encouraging these innovators allows us keep them motivated, and as such, ensures that our communities keep benefiting from their inventions. In light of the challenges facing the world today – be it energy security or safeguarding our natural resources – These innovators offer their concerted efforts. The United Arab Emirates, led by His Highness Sheikh Khalifa bin Zayed Al Nahyan, President of the Nation – May God protect him, is committed to exerting every effort towards encouraging such ambitious initiatives aimed at improving our collective quality of life.”

He added: We congratulate the winners of the Zayed Future Energy Prize, and encourage them all to continue in their efforts towards the creation of innovative solutions – impacting communities around the world. These are the ambassadors of innovation, the ambassadors of our Prize – these are the people who spread hope and aspiration and encourage the next generation of innovators.

We would also like to thank the members of the evaluation committees and the members of the Jury who have vastly contributed towards identifying tonight’s winners and towards helping the Prize become a hub for innovations and innovators from around the world.”

The Prize total of US$3.5 million was awarded in the Small and Medium Enterprises (SMEs) & Non-Governmental Organizations (NGOs) category to the UK’s Carbon Disclosure Project whilst India’s Orb Energy and Environmental Defence Fund of the US were first and second runners-up respectively in the same category. Dr Ashok Gadgil from the US won the Lifetime Achievement award while French company Schneider Electric received a Recognition Award in the Large Corporations category.

President Ólafur Ragnar Grímsson of Iceland, Chairman of the Prize’s Jury, said: “I am privileged to be a part of this platform and pay tribute to the leadership of Abu Dhabi for not only establishing the Prize but also for its profound message. It is extraordinary that a country such as the United Arab Emirates can come forward in this way; the people of Abu Dhabi should be very proud of this prize.”

The ceremony which marks the fourth year of the Prize commenced with an inspirational video tribute to the late founding father and President of the United Arab Emirates, Sheikh Zayed bin Sultan al Nahyan.

The video tribute was followed by a segment on the global ripple effect generated by the winners of the Prize who exemplify the wide-reaching and influential nature of the Prize itself.

Dr Sultan Ahmed Al Jaber, Director General of the Zayed Future Energy Prize, said: “It is our founding father, Sheikh Zayed bin Zayed Al Nahyan who 40 years ago, began his journey of instilling in us the importance of building bridges, instigating dialogue and forging friendships around the world and it is our leadership today that continues this vision.”

Dr Al Jaber attributed the increasing growth of the prize to its agility and ability to adapt to the fast moving dynamic sector, adding “It is the directives given to us by General Sheikh Mohamed bin Zayed Al Nahyan, of further enhancing the prize to expand our reach that has enabled us to reach innovators from around the globe.”

He commended the finalists for 2012, adding: “These are people that had the foresight to recognize that investing in the future is based on long term vision and the ability to innovate the technologies that the world so urgently needs.”

In the SME & NGO category, Carbon Disclosure Project was awarded US$1.5 million, while Orb Energy was named first runner-up with a cash prize of US$1 million and Environmental Defense Fund took away US$500,000 as the second runner-up.

All three finalists excelled in demonstrating clear impact through their work in disseminating solutions to further knowledge, creating awareness, as well as developing policies and technologies in renewable energy and sustainability.

Dr Ashok Gadgil, recipient of the Lifetime Achievement Award, received US$500,000 for his pioneering efforts as one of the leading modern inventors in the US for the Darfur stove.

Recipient of the Large Corporations award, Schneider Electric, received a recognition award from the Prize.

Paul Dickinson, Executive Chairman, Carbon Disclosure Project,awarded for its pioneering use of market-based tools to solve environmental issues, from cap and trade approach to acid rain pollutionsaid: “We are delighted and honored to be recognized by the Zayed Future Energy Prize for the work we have done at the Carbon Disclosure Project (CDP). Like the prize itself, CDP is committed to accelerating solutions that will meet the challenges of climate change, energy security and water scarcity. Winning this prize is a huge achievement and will help CDP to more rapidly catalyze change across the global economic system to prevent dangerous climate change, protect our natural resources and create long-term prosperity.”

Winner of the Lifetime Achievement Award, Dr Gadgil, who received the prize for his sustainable humanitarian work in Darfur – providing energy efficient cooking stoves known as Berkeley-Darfur stoves, cutting the need for firewood by 55%,said: “Being selected the winner for the Zayed Future Energy Prize is a great honor and tremendous validation of my lifelong passion and efforts for energy innovation and sustainability.

“Looking at the list of past prize winners and runners up – some of whose work I know well – I am impressed with the energy and ingenuity of this group, and I hope that we can work together, and inspire many others, to advance the aim of the Zayed Future Energy Prize – energy sustainability for the planet.”

Dr Gadgil further added: “Winning the Zayed Future Energy Prize deepens my commitment to energy innovation for sustainability. Together with my colleagues and co-workers, I will continue to advance the research, design, testing, and scale-up of fuel-efficient low-emission stoves for about three billion people (mostly women) that use biomass for cooking.”

On receiving the award, Jean-Pascal Tricoire, President and Chief Executive Officer of Schneider Electric,who won for their work towards making energy safe, reliable and efficientsaid: “The world is in urgent need of innovative solutions to create a new, sustainable energy future. The UAE’s commitment towards sustainable development, which takes inspiration from the vision of the UAE’s founding father, the late Sheikh Zayed Bin Sultan Al Nahyan and Abu Dhabi’s efforts in this domain are a decisive first step towards meeting and solving the global energy challenge.”

Members of the Jury of the Zayed Future Energy Prize present at the ceremony included His Excellency Ólafur Ragnar Grímsson, President of Iceland and Chairman of the Jury; His Excellency Ahmed Al Sayegh, Chairman of Masdar; Cherie Blair, Founder of the Cherie Blair Foundation, and Timothy Wirth, President of the United Nations Foundation and the Better World Fund.

Jury member, actor and environmentalist Leonardo DiCaprio, who could not attend, sent a video message to the audience:

“Greetings, I wish I could be with all of you tonight to honor this year’s exceptional winners of the Zayed Future Energy Prize, but unfortunately my schedule won’t allow me.

“It has been an honor this year to join the esteemed group of jury members, who together represent some of the world’s leading thinkers on the environment and on breakthrough energy technologies.

“The Prize serves two key purposes, First it encourages and acknowledges cutting edge innovators in our society, driving them to further breakthroughs. And at the same time the Prize raises much-needed public awareness about the clean energy solutions available to us and how they hold the key to preserving and protecting our planet for generations to come.

“Participating in the selection process and seeing just how many companies, individuals and organizations are making significant contributions towards a clean energy future gives me real hope that the transformation has begun. And all of us are part of it.

“Thank you and congratulations again,” DiCaprio concluded.

Tennis Grand Slam champion and education advocate Andre Agassi, and Dr Susan Hockfield, President of the Massachusetts Institute of Technology (MIT), also members of the ZFEP jury panel, were also unable to attend.

The awards ceremony culminated a stringent year-long, four-stage process. Nominations for the Zayed Future Energy Prize were launched in May 2011 through a globally targeted campaign. In August, at the close of nominations, the Prize had received a record 1,103 submissions of which 425 were submitted by September, 2011.

In the first stage of the evaluation process, an independent research and analysis firm conducted a diligent examination of each candidate’s application. During the second stage, a Review Committee met on 23-24 October to evaluate each candidate and culled the numbers to a select 33 candidates across all categories using a scoring matrix based on the Prize’s four criteria.

In the third stage of the judging process from 13-14 November, a Selection Committee comprising leading experts in the field of renewable energy and sustainability evaluated the shortlisted entries. Submissions scoring the highest made it to the fourth and final round. The finalists included three candidates for the Large Corporations category, three candidates for the Lifetime Achievement Award and seven candidates who could win first, second and third prize for the SME & NGO category.

The Zayed Future Energy Prize is awarded annually to large corporations, individuals and SMEs and NGOs that have made significant contributions to the future of energy, climate change and sustainability. The 2013 edition of the awards will feature the newly instituted Global High School Prize to inspire a new generation of leaders and innovators.

For more information on the prize, please visitwww.ZayedFutureEnergyPrize.com

- end –

About the Zayed Future Energy Prize

The Zayed Future Energy Prize was created in honour of the legacy of the late Founding Father and President of the United Arab Emirates, Sheikh Zayed bin Sultan Al Nahyan. The prize aims to inspire the next generation of global energy innovators to create solutions for the future. The Prize is awarded annually to individuals, companies or organisations that have made significant contributions in the global response to the future of energy, clim

and sustainable global energy resources.

More information can be foundon ZFEP through the Facebook Page: facebook.com/TZFEPor Twitter: http://twitter.com/zfep

Photo Caption:

Image 1: (center) HH General Sheikh Mohamed bin Zayed Al Nahyan Crown Prince of Abu Dhabi Deputy Supreme Commander of the UAE Armed Forces, and (right) HE Dr Sultan Ahmed Al Jaber CEO of Masdar, stand with 2012 Zayed Future Energy Prize winners. (left to right) Jean-Pascal Tricoire, President and CEO of Schneider Electric, Dr Ashok Gadgil, Paul Simpson, Chief Executive Officer, Carbon Disclosure Project, HH General Sheikh Mohamed bin Zayed Al Nahyan Crown Prince of Abu Dhabi Deputy Supreme Commander of the UAE Armed Forces, Damian Miller, CEO of Orb Energy, Eric Pooley, Senior Vice President, Stategy and Communications, Environmental Defense Fund

Contacts

APCO Worldwide

(JiWiN Public Relations)

Sam Elie Bassile

sbassile@apcoworldwide.com

+971 50 3965474